Results 121 to 130 of about 21,604,258 (289)
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by ...
Xiao Han +3 more
doaj +1 more source
Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy
Importance The commercialization of chimeric antigen receptor-T-cell (CAR-T) therapy has changed the landscape of treatment of hematological cancers. Numerous studies from the early 2000s paved the way for cell-based targeted therapeutics, which have ...
Spiegel, Jay Y. +2 more
core +1 more source
Sesamin reshapes the diabetic gut microbiota and increases microbiota‐associated indole‐3‐carboxaldehyde availability. ICA activates intestinal AhR signaling, enhances AhR occupancy at the Gcg promoter, and promotes GLP‐1 production. GLP‐1R signaling contributes to improved glucose tolerance and early insulin responses, linking microbial metabolism to ...
Zhichao Li +13 more
wiley +1 more source
Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic ...
Arora, Ena, MD +3 more
core +1 more source
From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies
Immunotherapy, particularly chimeric antigen receptor T cell (CAR‐T) therapy, has revolutionized the treatment of hematological malignancies and autoimmune diseases.
Yang Chen +7 more
doaj +1 more source
Advance in chimeric antigen receptor T-cell therapy for glioblastoma
Glioblastoma (GBM) has an extremely poor prognosis, and chimeric antigen receptor T-cell (CAR-T) therapy offers new hope for its treatment. This review systematically discusses the research progress of CAR-T therapy for GBM, analyzing the major ...
YUAN Feng +5 more
doaj +1 more source
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac +16 more
wiley +1 more source
This paper reported a 64-year-old, secondary central nervous system lymphoma (sCNSL) patient with COVID-19 infection during CD19 chimeric antigen receptor T-cell (CAR-T) therapy following autologous stem cell transplantation (ASCT).
Xiaoning Wang +5 more
doaj +1 more source
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang +36 more
wiley +1 more source
Progress in parabiotic mouse models: From origins to modern applications
This review traces the evolution of the parabiotic mouse model, from its origins to modern refinements in surgical technique and stability assessment. It highlights how heterochronic parabiosis has uncovered the rejuvenating effects of young blood and how the model, now integrated with multi‐omics and organoids, provides an irreplaceable platform for ...
Yalong Yang +5 more
wiley +1 more source

